Africa’s first-ever Phase 1 trial of long-acting injectable for malaria prevention launches in Rwanda
Medicines for Malaria Venture (MMV) and Rinda Ubuzima, a leading Rwandan health research organization, today announced the launch of a Phase 1b clinical trial for a potential long-acting injectable (LAI) for malaria prevention.